Introduction: Endoscopic submucosal dissection is widely employed in early gastric cancer (EGC). Foveolar phenotypes should be distinguished from the other differentiated EGC (DEGC) types because of their increased malignant potential. The phenotypic classification could be useful not only for investigating EGC tumorigenesis but also for evaluating the tumor aggressiveness to guide treatment decision making. Methods: On surgical tissue specimens, we studied the mucin phenotype of EGC to distinguish cases with a worse prognosis dictating different therapeutic options or a very close surveillance program. DEGC in our series were classified as mucin foveolar (51%) or mucin intestinal (49%) phenotype. We evaluated correlations among foveolar and intestinal phenotypic markers, tumor patterns, clinicopathologic features and prognostic and therapeutic implications. Immunohistochemistry (IHC) for MUC5AC and CDX2 was performed on 63 EGC patient specimens. MUCA5C was employed as gastric foveolar phenotypic marker and CDX2 as intestinal phenotypic marker. Results: Foveolar DEGC was significantly associated with larger tumor size (p=0.01), high grade (G2-G3) (p=0.001), vessel permeation (p=0.05), lymph node metastasis (p=0.001) and ulceration (p=0.001), whereas intestinal type DEGC was associated with low grade (p=0.001). Conclusion: IHC determination of the mucin phenotype is an easy, inexpensive method that can provide useful, sensitive markers distinguishing the foveolar or intestinal phenotype in DEGC. The precise identification of the foveolar type, featuring a poorer prognosis, should sound a warning bell mandating very close study of the lesion before endoscopic treatment or contraindicating endoscopic resection in favor of the open surgery option.
Introduction
Most patients with early gastric cancer can now hope for a better quality of life thanks to the recent advent of widespread minimally invasive surgical procedures including endoscopic mucosal resection and submucosal dissection. Early gastric cancer is an invasive carcinoma but it infiltrates no more deeply than the submucosa, regardless of lymph node metastases and tumor size. Many EGC cases have been identified in Japan and well described by Nakamura, 1 thanks to the very active screening of patients in this geographic area at high risk for gastric cancer. It is essential to identify early stage gastric carcinomas, and target the incipient phases of invasion and metastasis, because early detection and adequate surgical or endoscopic treatment yield a better outcome. The importance of the accurate staging of gastric tumors has become even more apparent since the new developments in endoscopic resection techniques. [2] [3] [4] Selected cases of EGC, which respond to specific endoscopic and pathological criteria, are to be considered susceptible to endoscopic treatment with radical intent, rather than open surgery. Therapeutic decision making for endoscopic versus open surgery resection of early gastric carcinoma (EGC) relies upon the clinicopathological findings indicating the risk of lymph nodes metastases (LNM). In EGC with little or no risk of LNM, endoscopic resection, especially endoscopic submucosal dissection (ESD), has become the standard treatment because it features minor patients trauma, less costs and has a higher safety margin, with maximal preservation of gastric function and an excellent long-term prognosis, comparable to that of open surgical resection. 5, 6 For these reasons, ESD is now contemplated as first-line treatment of early gastric cancer in Japanese guidelines. 7 The lesions to be considered for endoscopic resection, being at very low risk of lymph node metastasis, are the following: a) noninvasive neoplasia (dysplasia) independently of size; b) intramucosal differentiated-type adenocarcinoma, without ulceration (size ≤2 cm absolute indication, >2 cm expanded indication); c) intramucosal differentiated-type adenocarcinoma, with ulceration, size ≤3 cm (expanded indication); d) intramucosal undifferentiated-type adenocarcinoma, size ≤2 cm (expanded indication); e) differentiated-type adenocarcinoma with superficial submucosal invasion (sm1≤500 µm), and size ≤3 cm (expanded indication). Therefore, morphological classification of the EGC subtype is essential for prognostication and treatment decision making. Histologically, gastric carcinomas (GC) are classified under two main types, the intestinal and the diffuse type, depending on whether there are glandular structures, as described by Lauren, 8 corresponding to the differentiated and undifferentiated types described by Nakamura et al. [15] [16] [17] Controversies and conflicting results on the prognostic role of Muc5AC expression associated with the foveolar phenotype and cell origin in gastric cancer have ensued. CDX2 is expressed at the early stage of gastric carcinogenesis in intestinal phenotypic elements and could be associated with a suppressed expansion of malignant cells. 18, 19 Furthermore, CDX2 is expressed in the very early stage of gastric carcinogenesis in association with a shift from the gastric to the intestinal phenotypic expression. 20 This appears to occur at an earlier stage in differentiated cancers compared to undifferentiated forms and may be linked to this suppression of malignant cells expansion. Cdx2-positive GCs had a significantly better outcome than Cdx2-negative GCs. Loss of CDX2 may signal tumor progression in cases of early gastric cancer. 21, 22 Therefore, phenotypic classification may be useful not only for investigating the tumorigenesis of early gastric carcinoma but also for evaluating the tumor aggressiveness and supporting surgical decision making. Moreover, cases of differentiated type carcinoma with a pronounced trend toward invasion and metastasis, even in the early stage, have been observed. In these cases, endoscopic resection is 
Patients and methods

Patients characteristics
Paraffin-embedded specimens of 63 EGC tissues were collected from January 2006 to March 2018 at the IRCCS 'Saverio de Bellis'of Castellana Grotte (Ba, Italy). All experiments were performed in accordance with ethical standards, the Declaration of Helsinki, and according to national and international guidelines, and have been approved by review board IRCCS Giovanni Paolo II " Bari (Italy). Written informed consent was obtained from patients. The following clinicopathological characteristics were collected for all patients: age, gender, macroscopic features, histological type, tumor grade, presence of ulceration, vessel permeation, perineural infiltration and lymph node metastasis.
Pathological assessment
Histology was assessed in all tumors by two pathologists who reviewed FFPE tissue sections stained with hematoxylin and eosin (H&E), and a representative paraffin block from each specimen was chosen for IHC analysis. On H&E and PAS mucin-stained sections, the histological characteristics of cells, tumor grade, the presence of ulcerations, perineural infiltration, vessel permeation and the presence of lymph node metastasis were evaluated. The specimens were classified according to both European Society of Gastrointestinal Endoscopy and AJCC 8th edition (American Joint Committee on Cancer) guidelines. In this regard, in Table 1 the grade refers only to the intestinal phenotype because diffuse type carcinoma is high grade and classified as grade 3.
IHC evaluation
HC analysis for MUC5AC and CDX2 was performed in the FFPE of 63 patients with EGC. Tumor sections of 4 µm were freshly cut and dried at 60°C for 30 min. IHC analysis was carried out on the sections after deparaffinization for 30 mins and then rehydration in grades of alcohol. Antigen retrieval was performed at 90°C for 20 mins with CitratoBuffer. To assess MUC5AC, a foveolar epithelium glycoprotein, and CDX2, an intestine-specific transcription factor, we employed these antibodies on the EGC tissues (clone 45M1 at 1:100 
Results
Patient population
The clinicopathologic features of the 63 cases of EGC are summarized in Table 1 
Phenotypic expression of DEGC
To evaluate the origin and phenotypic expression of DEGC types, we analyzed Muc5AC (revealing foveolar mucin glycoprotein) and CDX2 (revealing intestinal cell origin) tissue expression in 33 (52.38%) DEGC. The correlation between Muc5AC or CDX2 expression and gender was not significant (p=0.07; 0.04) ( Table 3) . Muc5AC was observed in 17 (51%) of 33 EGC cases. Importantly, Muc5AC expression was absent in all 16 G1 cases (100%), while Muc5AC positivity in tumor cell membranes was detected in 9 G2 cases (100%) and 8 G3 cases (100%) ( Table 3) . On the other hand, Muc5AC positivity was expressed in all 17 (100%) cases presenting ulceration and perineural infiltration (17; 100%) but only in 13 of 17 cases with vessel permeation (Table 3) . Hence, the expression of MUC5AC was associated with aggressive tumor characteristics, including high grade (p=0.001), ulceration (p=0.001), vessel permeation (p=0.001) and perineural infiltration (p=0001). By contrast, CDX2 expression was present in 16 (49%) of 33 EGC cases and was found to be significantly associated with low-grade tumors (p=0.001). All 16 (100%) cases of positive CDX2 expression lacked the above-listed aggressive tumor characteristics (Table  3) . On the basis of the combined expression patterns of CDX2 and MUC5AC, the DEGC were classified as intestinal phenotype (CDX2 Importantly, not only does the foveolar phenotype feature a larger tumor size but also a greater percentage of cases infiltrating the submucosa (15;88%), while the intestinal phenotype featured a large percentage of intramucosal cases (12; 75%) (Table 4) .
Thus, foveolar-phenotype DEGC was associated with a more advanced histological grade (G2-G3), ulceration, that was present in all of these patients, and also a significantly greater vascular involvement.
Discussion
In the last two decades, endoscopic treatment of EGC with curative intent has been widely performed, adopting well-defined absolute and expanded inclusion criteria. To clarify gastric tumorigenesis it is essential to investigate phenotypic markers expression and correlations between clinicopathological findings in the early tumor phase. Approximately 30% of DGC express mainly gastric type mucin. 23 Differentiated foveolar EGC, measuring less than 2 cm in diameter, are universally recognized as treatable by ESD regardless of histological type. Differentiated gastric phenotype cancer, in the early phase, is prone to transformation to undifferentiated type cancer and to growth with deeper infiltration in the wall layers. This type of DGC should be distinguished from the others because of its tendency to invade and metastasize already during the incipient phase. 24 The importance of discriminating these phenotypes is also due to the fact that early gastric foveolar-phenotype differentiated adenocarcinomas are more aggressive, tend to be significantly larger tumors and exhibit higher rates of submucosal invasion than intestinal-phenotype EGC. Therefore, to clarify gastric tumorigenesis it is essential to investigate phenotypic markers expression, that is also driven by genetic alterations in the early tumoral phase. In literature, the reported incidence of gastric foveolar-phenotype differentiated adenocarcinoma appears to range from 7.9% to 23.9%. 11, 25 In our series, in the DEGC cases, we found a higher percentage of foveolar phenotype tumors. In the present study, the intestinal origin and foveolar phenotypic mucin glycoprotein expression was examined in 33 (52.38%) DEGC. On the basis of the combined expression patterns of CDX2 and MUC5AC, the DEGC were classified as 16 (49%) intestinal mucin phenotype (CDX2 + , Muc5AC − ) and 17 (51%) foveolar phenotype (CDX2 − , Muc5AC + ) (Figure 1 ).
In particular, foveolar phenotype DEGC were significantly associated with high grade (G2-G3) (p=0.001), large tumor size (p=0.01), vessel permeation (p=0.05), lymph node metastasis (p=0.001) and ulceration (p=0.001), whereas intestinal phenotype DEGC were significantly associated with low grade (p=0.001) and no aggressive tumor characteristics. Moreover, there were distinct differences in tumor aggressiveness according to the phenotypic marker expressions of early-stage gastric differentiatedtype tumors. Differentiated-type gastric carcinomas with a foveolar phenotype have been suggested to be more likely to transform into undifferentiated-type carcinoma. In literature (14) , among early gastric carcinomas, the gastric phenotype is reported to be an independent factor associated with lymph node metastasis. In our 63 cases of EGC, the 17 foveolar mucin phenotype cases, as defined by IHC assay, showed a greater lesion diameter (2.86 vs 1.77 cm) and more submucosal involvement (88% vs 25%) than the intestinal mucin phenotype. Confirming the more aggressive nature of the foveolar phenotype, the loss of CDX2 occurs as a signal of tumor progression from early to advanced GC, marking the shift to gastric phenotype expression. The worldwide diffusion and standardization of endoscopic treatment, the refinements in ESD techniques, instruments and devices defined in the last two decades, together with the extension of the criteria and the conditions for eligibility for less invasive resective procedures must work in parallel with a better knowledge of the biology of this heterogeneous tumor burden, searching for multifocality with synchronous and metachronous lesions. ESD is a highly effective treatment modality for EGC in cases that meet the absolute and expanded criteria described in current guidelines and is also a valid resource to identify untreatable patients, who are often elderly with severe comorbidities and cannot undergo surgery due to the high operation risk. 26 For these patients, palliative
ESD remains the unique opportunity to avoid serious complications such as perforation or hemorrhage or stenosis requiring urgent salvage measures. Patients with gastric mucin phenotype tumors have a poorer prognosis than those with intestinal mucin phenotype, suffering more peritoneal recurrence after curative resection, whereas hematogenous recurrence occurred more frequently in the intestinal mucin phenotype. 27 As for pedunculated colonic adenomas containing adenocarcinoma, endoscopically treated, also in EGC accurate evaluation of the patterns indicative of greater LNMs risk is the main criterion dictating the treatment choice and later evaluating its successful outcome. Therefore, all possible additional evaluation methods serving to indicate those cases that can safely undergo endoscopic resection procedures, with curative intent, ranging from echo-endoscopy to assess the submucosal invasion level, to imaging studies to exclude LNM, must be employed. Our study suggests that IHC evaluation of the mucin phenotype, widely considered to indicate a negative prognosis if of foveolar phenotype, offers a useful support to treatment decision making. This research underlines that the immunohistochemical profile of DEGC mucin expression, as a prognostic factor, should be an integral part of the preoperative phase investigation guiding therapeutic decision making. In conclusion, IHC determination of CDX2 and MUC5AC is an easy, inexpensive method and provides useful sensitive markers discriminating the foveolar from the intestinal phenotype in DEGCs. The identification of foveolar phenotype EGC should ring a warning bell, mandating a very close study of the lesion before endoscopic treatment or contraindicating endoscopic resection procedures, favoring an open surgery approach, in the absence of contraindications, or a very close surveillance program following endoscopic dissection to screen for local recurrence and tumor metastasis elsewhere in the gastric cavity.
Pathological assessment
Histology was assessed in all tumors by two pathologists who reviewed FFPE tissue sections stained with hematoxylin and eosin (H&E), and a representative paraffin block from each specimen was chosen for IHC analysis. On H&E and PAS mucin-stained sections, the histological characteristics of cells, tumor grade, the presence of ulcerations, perineural infiltration, vessel permeation and the presence of lymph node metastasis were evaluated. The specimens were classified according to both European Society of Gastrointestinal Endoscopy and AJCC 8th edition (American Joint Committee on Cancer) guidelines.
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